Bristol Myers Squibb (CELG-RI) Free Cash Flow (2009 - 2026)

Bristol Myers Squibb has disclosed Free Cash Flow across 18 years of filings, most recently posting $757.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 55.31% year-over-year to $757.0 million; the TTM figure through Mar 2026 stood at $11.9 billion (down 9.0% YoY), while the FY2025 annual figure was $12.8 billion, down 7.87% from the prior year.
• Free Cash Flow slipped to $757.0 million in Q1 2026, from $1.6 billion in the prior quarter.
• Over the last five years, Free Cash Flow for CELG-RI reached as high as $6.0 billion in Q3 2025 and fell as low as $757.0 million in Q1 2026.
• The 5-year median for Free Cash Flow is $3.0 billion (2022), against an average of $3.1 billion.
• The widest YoY moves for Free Cash Flow: up 72.29% in 2025, down 60.5% in 2025.
• A 5-year view of Free Cash Flow shows it stood at $3.0 billion in 2022, then jumped by 32.5% to $3.9 billion in 2023, then gained by 3.54% to $4.1 billion in 2024, then sank by 60.5% to $1.6 billion in 2025, then plunged by 52.81% to $757.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $757.0 million, $1.6 billion, and $6.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.